SIGX2649 / Signet Therap - LARVOL DELTA

A pan-TEAD inhibitor, SIGX2649, blocks Hippo-YAP/TAZ signaling pathway and suppresses solid tumor growth in preclinical studies (AACR 2026) - "In vivo, SIGX2649 exhibited robust antitumor efficacy in xenograft models, favorable pharmacokinetics, and minimal hepatic- or renal- targeted toxicity compared with other TEAD inhibitors under comparable efficacy. Combined with RAS-pathway inhibitors, SIGX2649 elicits pronounced synergistic responses in KRAS-mutant solid tumors.The robust efficacy and considerable safety characteristics presented by SIGX2649 in preclinical trials support its potential to serve as a highly promising small-molecule therapeutic in future cancer treatment."

Preclinical • Liver Cancer • Mesothelioma • Oncology • Solid Tumor • KRAS • NF2 • TEAD1 • VGLL4